MIRM
NASDAQMirum Pharmaceuticals Inc.
Price$91.92-2.39 (-2.54%)
01:30 PM07:45 PM
News · 26 weeks105-65%
2025-10-262026-04-19
Mix6090d
- SEC Filings22(37%)
- Insider22(37%)
- Other13(22%)
- Earnings2(3%)
- Analyst1(2%)
Latest news
25 items- SECSEC Form DEFA14A filed by Mirum Pharmaceuticals Inc.DEFA14A - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
- SECSEC Form DEF 14A filed by Mirum Pharmaceuticals Inc.DEF 14A - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
- INSIDERSEC Form 4 filed by Ramasastry Saira4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- PRMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on April 10, 2026, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 13,700 shares of common stock and 18,200 restricted stock units ("RSUs") to 12 new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $95.20 per share, which is equal to the closing price of Mirum's common stock on April
- SECAmendment: Mirum Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Mirum Pharmaceuticals Inc.SCHEDULE 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- INSIDERPRESIDENT AND COO Radovich Peter converted options into 30,220 shares and sold $1,519,015 worth of shares (16,515 units at $91.98), increasing direct ownership by 52% to 40,272 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Quan Joanne converted options into 13,334 shares and sold $670,243 worth of shares (7,287 units at $91.98), increasing direct ownership by 47% to 18,864 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERDirector Ramasastry Saira exercised 2,000 shares at a strike of $23.51 and sold $181,520 worth of shares (2,000 units at $90.76) (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Peetz Christopher converted options into 75,000 shares and sold $3,769,714 worth of shares (40,985 units at $91.98), increasing direct ownership by 21% to 194,309 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Bjerkholt Eric converted options into 13,334 shares and sold $670,243 worth of shares (7,287 units at $91.98), increasing direct ownership by 14% to 49,788 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERSVP, GLOBAL CONTROLLER Howe Jolanda converted options into 8,658 shares and sold $435,239 worth of shares (4,732 units at $91.98), increasing direct ownership by 87% to 8,429 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- PRMirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases- Study designed to support potential label expansion into additional settings of cholestatic pruritus - Topline data expected in Q4 2026 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced completion of enrollment in EXPAND, a Phase 3 randomized, double-blind, placebo-controlled study evaluating LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older with rare cholestatic liver diseases, including biliary atresia. Cholestatic liver diseases are characterized by impaired bile flow, resulting in elevated serum bile acids, severe pruritus, and significantly reduced quality of life. While LIVMARLI is appr
- PRMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on March 11, 2026, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 5,400 shares of common stock and 6,800 restricted stock units ("RSUs") to five new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $91.75 per share, which is equal to Mirum's closing trading price on March 11, 2026, a
- INSIDERPRESIDENT AND COO Radovich Peter exercised 5,912 shares at a strike of $15.87, increasing direct ownership by 29% to 26,567 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- PRMirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus- Phase 3 AZURE-1 enrollment complete - Phase 3 AZURE-4 screening complete - Topline AZURE-1 and AZURE-4 results expected in 2H 2026 - AZURE-1 and AZURE-4 to form the basis of Mirum's U.S. BLA Submission Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase 3 AZURE-4 study, both evaluating brelovitug for the treatment of chronic hepatitis delta virus (HDV). Achievement of these milestones confirms the expected timing of topline 24-week data in the second half of 2026. AZURE-1 and AZURE-4 together will form the basis of Mirum's U.S. BLA submission for br
- SECSEC Form S-3ASR filed by Mirum Pharmaceuticals Inc.S-3ASR - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
- SECSEC Form S-8 filed by Mirum Pharmaceuticals Inc.S-8 - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)